Insights that may inform optimal use of DMTs

It is hoped that in the near future, treatment selection will be guided by clinical characteristics and molecular biomarkers.¹ To this end, there is a great deal of ongoing research into predictors of response: at this year’s ECTRIMS–ACTRIMS, for example, Dominguez-Mozo and colleagues showed that response to anti-α4-integrin treatment could be predicted using combinations of clinical